Author:
Hudak Mark L.,Tan Rosemarie C.,Frattarelli Daniel A. C.,Galinkin Jeffrey L.,Green Thomas P.,Neville Kathleen A.,Paul Ian M.,Van Den Anker John N.,Papile Lu-Ann,Baley Jill E.,Bhutani Vinod K.,Carlo Waldemar A.,Cummings James,Kumar Praveen,Polin Richard A.,Wang Kasper S.,Watterberg Kristi L., ,
Abstract
Maternal use of certain drugs during pregnancy can result in transient neonatal signs consistent with withdrawal or acute toxicity or cause sustained signs consistent with a lasting drug effect. In addition, hospitalized infants who are treated with opioids or benzodiazepines to provide analgesia or sedation may be at risk for manifesting signs of withdrawal. This statement updates information about the clinical presentation of infants exposed to intrauterine drugs and the therapeutic options for treatment of withdrawal and is expanded to include evidence-based approaches to the management of the hospitalized infant who requires weaning from analgesics or sedatives.
Publisher
American Academy of Pediatrics (AAP)
Subject
Pediatrics, Perinatology and Child Health
Cited by
725 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献